|
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Clinical research trials and 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma. 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma clinical trial. Human subjects often get the best healthcare available for their 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "5" Clinical Trials Conditions > 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma  506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
For Condition: recurrent diffuse small lymphocytic/marginal zone lymphoma,angioimmunoblastic T-cell lymphoma,recurrent grade I follicular small cleaved cell lymphoma,small intestine lymphoma,recurrent adult T-cell leukemia/lymphoma,Waldenstrom's Macroglobulinemia,recurrent grade II follicular mixed cell lymphoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , M.D. Anderson Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma.
Details: OBJECTIVES: I. Determine the response rate, failure free survival, and progression free survival of patients with recurrent or refractory indolent B-cell non-Hodgkin's lymphoma or peripheral T-cell lymphoma when treated with 506U78. II. Assess the pharmacokinetics and toxicity of this treatment in these patients. PROTOCOL OUTLINE: Patients receive 506U78 IV over 120 minutes on days 1, 3, and 5. Treatment continues every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 51-111 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of recurrent or refractory indolent B-cell non-Hodgkin's lymphoma or peripheral T-cell lymphoma; Waldenstrom's macroglobulinemia; Lymphoplasmacytoid; Small lymphocytic; Marginal zone; Follicular small cleaved cell; Follicular mixed cell; All peripheral T-cell entities in REAL classification - No prior or concurrent evidence of transformation to large cell or follicular large cell lymphoma - No B-cell anaplastic large cell lymphoma, cutaneous T-cell lymphoma or any of its variants, and/or histologic transformation of cutaneous T-cell lymphoma - Bidimensionally measurable disease - No active CNS disease --Prior/Concurrent Therapy-- - Biologic therapy: No more than 1 prior immunotherapy regimen; No prior stem cell or bone marrow transplant - Chemotherapy: No more than 2 prior chemotherapy regimens (3 if one was chemoimmunotherapy); No prior 506U78 - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: Not specified - Other: At least 3 weeks since prior anticancer treatment --Patient Characteristics-- - Age: 16 and over - Performance status: Zubrod 0-2 - Life expectancy: Not specified - Hematopoietic: Unless due to marrow or splenic involvement by lymphoma: Absolute neutrophil count at least 1,000/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN); SGPT no greater than 2.5 times ULN - Renal: Creatinine clearance greater than 50 mL/min - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; HIV negative; No other prior malignancy in past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix; No sensory or motor neuropathy grade 2 or greater; No history of seizures; No medical, psychiatric, or social condition that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AndreasSarris, Study Chair, M.D. Anderson Cancer Center
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Additional Information:
Study ID Numbers: CDR0000067894; MDA-ID-99208,NCI-430
Study Start Date: April 2000
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005950
Other Recurrent Grade Ii Follicular Mixed Cell Lymphoma Studies:
1. Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia
2. Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
3. Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
4. FR901228 in Treating Patients With Hematologic Cancer
5. Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Related Studies:
Other recurrent grade II follicular mixed cell lymphoma Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
|
|
|
|
|
|
|
|
